SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

September 10, 2026

Study Completion Date

September 10, 2030

Conditions
Intracranial Aneurysm
Interventions
DEVICE

The SEAL™ Saccular Endovascular Aneurysm Lattice System

All adult subjects between 22 and 80 years of age and presenting with an unruptured or ruptured saccular Wide Neck intracranial aneurysm with less or equal to 19 mm in its equatorial width (2mm-19mm range) that in the opinion of the Principal Investigator (PI) requires treatment and suitable candidate for intrasaccular flow diversion treatment, who meet all eligibility criteria, will be considered for study enrollment.

Trial Locations (6)

10016

RECRUITING

NYU Langone Health, New York

11794

RECRUITING

Stony Brook University Hospital, Stony Brook

60005

RECRUITING

Endeavor Health - Northwest Community Hospital, Arlington Heights

60201

RECRUITING

Endeavor Health - Evanston Hospital, Evanston

60540

RECRUITING

Endeavor Health- Edward Hospital, Naperville

08103

RECRUITING

The Cooper Health System, Camden

Sponsors
All Listed Sponsors
lead

Galaxy Therapeutics INC

INDUSTRY